

A clinical study testing if a daily low dose of an antibiotic, ciprofloxacin, given during the first part of chemotherapy treatment to children with newly diagnosed ALL would reduce the risk of infection

Submission date 08/01/2021	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 20/01/2021	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 12/05/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims:

Acute Lymphoblastic Leukaemia (ALL) is one of the commonest forms of childhood cancer. Treatment has improved and survival rates are now high. ALL treatment involves chemotherapy which reduces the child's ability to fight infections. Infection is now one of the commonest causes of death in children with ALL, and this is most likely to happen in the first five weeks of treatment – called "Induction".

In children with other types of leukaemia and in children whose ALL has come back after treatment (relapsed), it has been shown that giving a daily, low dose of antibiotics every day can reduce the risk of infection by about a half, but nobody has tested it in children the first time they have treatment for ALL.

A new research study to look at how best to treat childhood ALL called ALLTogether-1 is open in the UK and across Europe. Our study, called CiproPAL, will work alongside the ALLTogether-1 study in the UK. CiproPAL will aim to answer the question "Does adding a daily, low-dose antibiotic (called ciprofloxacin) during the first part of chemotherapy treatment (induction) reduce the risk of infection in children, age 1-17 years old, with new ALL?"

Who can participate?

Children, aged 1-17 years with new ALL and are taking part in the ALLTogether-1 research study. They will have give their consent to take part in CiproPAL or their parents give consents on their behalf.

What does the study involve?

Each child will receive either the antibiotic or no antibiotic – the decision will be made randomly by a computer. We will then look at whether they get infections.

We will do tests to see if the infections that make children unwell and whether the bacteria that usually live in us are more resistant to antibiotics. This will help to decide whether using

ciprofloxacin is a good idea. The tests to see if the infections that make children unwell are resistant to antibiotics will be done as part of the normal care of the children – we will just collect the information to be used. The test for bacteria that live in us will be done by taking a sample of stool, or if the patient is finding it difficult to poo, a swab (a bit like cotton wool on a stick) that is rubbed onto the bottom. It does not hurt. The swab can be done by the patient, their carer, or a healthcare professional. It can be done when they are awake or when they are having an anaesthetic (for their other leukaemia treatment). We will ask for 5 of these samples to be done for each child over a year from when they join CiproPAL. These samples (of stool or swabs) will be optional – patients can still take part in CiproPAL whether they are done or not.

What are the possible benefits and risks of participating?

Giving children regular antibiotics might change how well the infections respond to antibiotics in the future (“resistance”). Tests will be done to look at whether this happens on CiproPAL. We hope that children who receive the antibiotics will have less infections during the induction stage of their treatment.

Where is the study run from?

CiproPAL is being run in NHS children's hospitals in the UK, who are also seeing patients for the ALLTogether-1 research study.

When is the study starting and how long is it expected to run for?

December 2020 to December 2031

Who is funding the study?

National Institute of Health Research (NIHR) (UK)

Who is the main contact?

Stephanie Argue (public), ctc.cipropal@ucl.ac.uk

Dr Robert Phillips (scientific), bob.phillips@york.ac.uk

Study website

<http://www.ctc.ucl.ac.uk/Trials.aspx>

Contact information

Type(s)

Public

Contact name

Mrs Stephanie Argue

Contact details

Haematology Trials Group
Cancer Research UK and UCL Cancer Trials Centre
90 Tottenham Court Road
London
United Kingdom
W1T 4TJ
+44 (0)207 679 9867
ctc.cipropal@ucl.ac.uk

Type(s)

Scientific

Contact name

Dr Robert Phillips

ORCID ID

<https://orcid.org/0000-0002-4938-9673>

Contact details

Centre for Reviews and Dissemination

University of York

York

United Kingdom

YO10 5DD

+44 (0)1904 321099

bob.phillips@york.ac.uk

Additional identifiers

EudraCT/CTIS number

2021-000341-40

IRAS number

293372

ClinicalTrials.gov number

NCT04678869

Secondary identifying numbers

129038, NIHR130848,1004004

Study information

Scientific Title

CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia): a randomised trial to assess the use of ciprofloxacin prophylaxis to prevent bacterial infection in children treated on the induction phase of the ALLTogether-1 treatment protocol

Acronym

CiproPAL

Study objectives

1. To assess the efficacy of ciprofloxacin prophylaxis in the reduction of infection during the induction phase of treatment for paediatric Acute Lymphoblastic Leukaemia within the ALLTogether-1 Trial
2. To evaluate the impact of ciprofloxacin prophylaxis on antimicrobial resistance, both of invasive infections and colonising organisms

Ethics approval required

Ethics approval required

Ethics approval(s)

1. Approved 20/08/2020, HCRW Wales (2 Redman Place, Cardiff, CF14 7EF, United Kingdom; +44 (0)292 2940931; HCRW.approvals@wales.nhs.uk), ref: 20/WM/0205

2. Approved 25/11/2021, London – Brent REC (2 Redman Place, Stratford, London , E20 1JQ, United Kingdom; +44 (0)2071048131; brent.rec@hra.nhs.uk), ref: 21/LO/0752

Study design

Interventional randomized controlled trial with internal pilot study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Reduction in risk of infection during the induction phase of treatment for paediatric acute lymphoblastic leukaemia

Interventions

Treatment arm:

Drug - Ciprofloxacin

Intervention - Prophylactic ciprofloxacin (10mg/kg BD, enteral/IV), to be given daily during the induction phase (over 4 weeks)

Control arm:

Drug: Antibiotic

Control - Standard of care antibiotic as per local policy

Following pre-randomisation assessments, using an electronic randomisation system, eligible patients will be allocated to an intervention arm stratified by intensity of chemotherapy (low-intensity vs high-intensity), age (<10 years vs >10 years), antibiotic use at randomisation (patients given antibiotics at diagnosis for proven/suspected infection vs no antibiotics) and trial centre. Both arms will be followed up for at least 72 months in total (12 months of active follow-up and at least 60 months of passive follow-up)

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Ciprofloxacin

Primary outcome measure

Rate of sterile site bacterial infections during induction, measured at approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction, using patient records

Secondary outcome measures

Current secondary outcome measures as of 10/01/2025 were assessed using patient records unless otherwise noted:

1. Febrile episodes, febrile neutropenia, severe infection (defined as the need for organ support or critical care intervention) and infection-related death.
 - 1.1. Fever is defined as temperature $\geq 38^{\circ}\text{C}$ (as per CTCAE v5.0).
 - 1.2. Febrile neutropenia is defined as neutrophil count $\leq 0.5 \times 10^9/\text{L}$ and either a single temperature of $>38.3^{\circ}\text{C}$ or a sustained temperature of $>38^{\circ}\text{C}$ for more than one hour.
2. Antibiotic exposure relating to infections which result in an inpatient hospital stay: This will be reported as days on therapy per 100 patient days per antibiotic.

Total exposure for IV antibiotics and IV+oral will be described. Separate analysis will be performed looking specifically at the differences:

 - 2.1. Prophylactic antibiotics include ciprofloxacin (intervention), prophylaxis for *Pneumocystis jirovecii* infection (usually with co-trimoxazole on two days per week), and prophylaxis against urinary or respiratory infections.
 - 2.2. Empirical antibiotics are those given prior to the identification of a specific infection and are usually defined within a centre's febrile neutropenia protocol.
- 2.1. Treatment antibiotics are those targeted at a particular clinically or microbiologically defined infection.
3. Patterns of antimicrobial resistance and their changes over time in A) bacterial isolates from blood cultures or other sterile sites, B) stool or peri-rectal swab isolates.
 - 3.1. Local sites to analyse, looking at standard resistance patterns and report for each antibiotic class as resistant, intermediate or sensitive.
4. Secondary infections: *Clostridium difficile* infections (see current definitions) and invasive fungal infections (following the 2020 EORTC definition).
5. Specific quinolone adverse effects, including tendinitis and tendinopathy, visual disturbance, seizures, polyneuropathy and hepatic dysfunction which should be coded as per CTCAE v5.0.
6. Health economic analysis to assess the cost-effectiveness of ciprofloxacin prophylaxis versus no prophylaxis for patients receiving induction therapy for ALL.

Measured using patient records unless otherwise noted:

1. Rate of febrile episodes during induction, measured at approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction
2. Rate of febrile neutropenia during induction, measured at approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction
3. Rate of severe infection and infection-related deaths during induction, measured at

approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction

4. Rates of AMR (antimicrobial resistance) measured from randomisation until end of trial declaration (approximately 10 years) measured using results from stool samples or peri-rectal swab cultures

5. Rate of antibiotic exposure during induction, measured at approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction

6. Rate of secondary infections during induction, measured at approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction

7. Quinolone side effects during induction, measured at approximately 1 month from randomisation until the start of consolidation, discontinuing protocol, antileukaemic therapy or death post induction

8. Cost-effectiveness of ciprofloxacin prophylaxis versus no prophylaxis - model-based health economic analysis measured using the EQ-5D (5L) questionnaire which is being collected on the ALL Together-1 study, on which the CiproPAL participants are enrolled

Overall study start date

01/12/2020

Completion date

31/12/2031

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 10/01/2025:

1. Paediatric patients (1-17 years inclusive) with de-novo Acute Lymphoblastic Leukaemia treated on ALLTogether1 in the UK as soon as possible after commencing induction, preferably in the first 5-8 days of therapy, up to 14 days is acceptable.
2. Written informed consent.

Previous participant inclusion criteria as of 15/11/2023 to 10/01/2025:

1. Paediatric patients (1 - 17 years inclusive) with de-novo acute lymphoblastic leukaemia treated on ALLTogether-1 in the UK in the first 14 days of therapy (but ideally day 5-8)
2. Written informed consent

Previous participant inclusion criteria:

1. Paediatric patients (1 - 17 years inclusive) with de-novo acute lymphoblastic leukaemia treated on ALLTogether-1 in the UK in the first 5 days of therapy
2. Written informed consent

Participant type(s)

Patient

Age group

Child

Lower age limit

1 Years

Upper age limit

17 Years

Sex

Both

Target number of participants

1,052

Key exclusion criteria

1. Non-participants of the ALLTogether-1 trial
2. Patients with Down syndrome who already receive ciprofloxacin prophylaxis
3. Patients with chronic active arthritis
4. Other contraindication to fluoroquinolones

Date of first enrolment

29/06/2022

Date of final enrolment

31/12/2025

Locations**Countries of recruitment**

England

Northern Ireland

Scotland

United Kingdom

Wales

Study participating centre

University College London Hospital

225 Euston Road

London

United Kingdom

NW1 2BU

Study participating centre

Addenbrooke's Hospital

Hills Road

Cambridge
United Kingdom
CB2 0QQ

Study participating centre
Royal Manchester Children's Hospital
Oxford Road
Manchester
United Kingdom
M13 9WL

Study participating centre
Bristol Royal Hospital for Children and Bristol Haematology and Oncology Centre
Upper Maudlin Street
Bristol
United Kingdom
BS2 8BJ

Study participating centre
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
United Kingdom
NE1 4LP

Study participating centre
John Radcliffe Hospital
Headley Way
Headington
Oxford
United Kingdom
OX3 9DU

Study participating centre
Alder Hey Children's Hospital
Eaton Road
Liverpool
United Kingdom
L12 2AP

Study participating centre
Southampton General Hospital
Tremona Road
Southampton
United Kingdom
SO16 6YD

Study participating centre
Leeds General Infirmary
Great George Street
Leeds, West Yorkshire
United Kingdom
LS1 3EX

Study participating centre
Sheffield Children's Hospital
Western Bank
Sheffield
United Kingdom
S10 2TH

Study participating centre
Queen's Medical Centre
Clifton Boulevard
Derby Rd
Nottingham
United Kingdom
NG7 2UH

Study participating centre
Royal Hospital for Children and Young People
9 Sciennes Road
Edinburgh
United Kingdom
EH9 1LF

Study participating centre
Leicester Royal Infirmary
Infirmary Square
Leicester

United Kingdom
LE1 5WW

Study participating centre
Royal Aberdeen Children's Hospital
Westburn Road
Aberdeen
United Kingdom
AB25 2ZG

Study participating centre
Great Ormond Street Hospital for Children
Great Ormond Street
London
United Kingdom
WC1N 3JH

Sponsor information

Organisation
University College London

Sponsor details
Joint Research Office
Gower Street
London
England
United Kingdom
WC1E 6BT
+44 (0)207 3809995
ctc.sponsor@ucl.ac.uk

Sponsor type
University/education

Website
<https://www.ucl.ac.uk/joint-research-office/>

ROR
<https://ror.org/02jx3x895>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Dissemination will be through academic outputs (papers, presentations, and reports) and connections with charities, patient and parent organisations, and international guideline groups. CiproPAL may change the management of children and young people with ALL across the UK and globally.

Intention to publish date

15/06/2025

Individual participant data (IPD) sharing plan

Requests for de-identified data should be made in writing to the Trials Group Lead at the CR UK and UCL Cancer Trials Centre. Please see the UCL CTC website for access criteria and link to contact <http://www.ctc.ucl.ac.uk/DataSampleSharing.aspx>

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 1	22/09/2021	15/12/2021	No	No